Madrigal Net Income vs Research Development Analysis

MDGL Stock

USD 312.00 1.13 0.36%

Madrigal Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Madrigal Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Madrigal Pharmaceuticals is a good investment. Please check the relationship between Madrigal Pharmaceuticals Net Income and its Research Development accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.

Net Income vs Research Development

Net Income vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Madrigal Pharmaceuticals Net Income account and Research Development. At this time, the significance of the direction appears to have pay attention.

The correlation between Madrigal Pharmaceuticals' Net Income and Research Development is -0.99. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Research Development in the same time period over historical financial statements of Madrigal Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Madrigal Pharmaceuticals' Net Income and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Madrigal Pharmaceuticals are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Net Income i.e., Madrigal Pharmaceuticals' Net Income and Research Development go up and down completely randomly.

Correlation Coefficient

-0.99

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Madrigal Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Madrigal Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Research Development

Most indicators from Madrigal Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Madrigal Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.At this time, Madrigal Pharmaceuticals' Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 75.06 this year, although Enterprise Value Over EBITDA will most likely fall to (12.00).

Madrigal Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Common Stock	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Short Term Investments	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Short Long Term Debt Total	Non Current Liabilities Total	Short Term Debt	Net Receivables
Total Assets		0.95	-0.36	0.89	0.82	0.76	-0.36	0.75	0.72	0.32	-0.34	-0.2	-0.59	0.69	0.42	0.18	0.47	1.0	0.93	0.78	0.32	1.0	0.7	0.74	-0.47	-0.32
Total Stockholder Equity	0.95		-0.41	0.86	0.62	0.52	-0.41	0.53	0.48	0.18	-0.34	-0.35	-0.33	0.45	0.5	0.03	0.43	0.95	0.92	0.6	0.18	0.94	0.47	0.5	-0.52	-0.31
Common Stock Total Equity	-0.36	-0.41		-0.58	0.06	-0.13	1.0	-0.22	-0.15	-0.24	-0.22	0.29	-0.24	-0.18	-0.31	-0.06	-0.23	-0.39	-0.32	-0.16	-0.24	-0.39	-0.04	-0.11	0.82	-0.23
Common Stock Shares Outstanding	0.89	0.86	-0.58		0.66	0.65	-0.58	0.75	0.7	0.2	-0.38	-0.26	-0.43	0.65	0.42	0.02	0.52	0.88	0.76	0.76	0.2	0.88	0.49	0.54	-0.65	-0.34
Other Stockholder Equity	0.82	0.62	0.06	0.66		0.94	0.06	0.9	0.92	0.38	-0.4	0.13	-0.94	0.88	0.14	0.31	0.4	0.8	0.7	0.89	0.38	0.8	0.89	0.89	-0.1	-0.39
Total Liab	0.76	0.52	-0.13	0.65	0.94		-0.14	0.95	0.96	0.49	-0.22	0.19	-0.92	0.94	0.1	0.42	0.38	0.76	0.61	0.87	0.49	0.76	0.95	0.96	-0.2	-0.22
Common Stock	-0.36	-0.41	1.0	-0.58	0.06	-0.14		-0.23	-0.16	-0.24	-0.21	0.29	-0.24	-0.18	-0.31	-0.06	-0.23	-0.4	-0.33	-0.16	-0.24	-0.39	-0.05	-0.12	0.82	-0.23
Other Current Liab	0.75	0.53	-0.22	0.75	0.9	0.95	-0.23		0.99	0.46	-0.26	0.11	-0.86	0.92	0.14	0.34	0.5	0.75	0.57	0.93	0.46	0.75	0.81	0.83	-0.31	-0.24
Total Current Liabilities	0.72	0.48	-0.15	0.7	0.92	0.96	-0.16	0.99		0.46	-0.27	0.14	-0.9	0.96	0.11	0.37	0.46	0.72	0.54	0.92	0.46	0.72	0.84	0.85	-0.22	-0.26
Property Plant And Equipment Net	0.32	0.18	-0.24	0.2	0.38	0.49	-0.24	0.46	0.46		0.52	0.48	-0.41	0.43	-0.34	0.93	0.46	0.37	0.4	0.44	1.0	0.37	0.5	0.51	-0.13	0.51
Current Deferred Revenue	-0.34	-0.34	-0.22	-0.38	-0.4	-0.22	-0.21	-0.26	-0.27	0.52		0.13	0.32	-0.22	-0.18	0.46	-0.3	-0.26	-0.21	-0.24	0.52	-0.26	-0.15	-0.13	-0.14	0.99
Net Debt	-0.2	-0.35	0.29	-0.26	0.13	0.19	0.29	0.11	0.14	0.48	0.13		-0.3	0.12	-0.95	0.53	0.17	-0.2	-0.05	0.07	0.48	-0.19	0.25	0.22	0.29	0.11
Retained Earnings	-0.59	-0.33	-0.24	-0.43	-0.94	-0.92	-0.24	-0.86	-0.9	-0.41	0.32	-0.3		-0.87	0.04	-0.39	-0.31	-0.57	-0.45	-0.83	-0.41	-0.57	-0.87	-0.85	-0.09	0.32
Accounts Payable	0.69	0.45	-0.18	0.65	0.88	0.94	-0.18	0.92	0.96	0.43	-0.22	0.12	-0.87		0.14	0.36	0.29	0.68	0.53	0.87	0.43	0.69	0.84	0.85	-0.21	-0.22
Cash	0.42	0.5	-0.31	0.42	0.14	0.1	-0.31	0.14	0.11	-0.34	-0.18	-0.95	0.04	0.14		-0.4	-0.09	0.42	0.23	0.16	-0.34	0.42	0.05	0.08	-0.32	-0.16
Non Current Assets Total	0.18	0.03	-0.06	0.02	0.31	0.42	-0.06	0.34	0.37	0.93	0.46	0.53	-0.39	0.36	-0.4		0.47	0.22	0.26	0.28	0.93	0.22	0.47	0.45	0.15	0.44
Non Currrent Assets Other	0.47	0.43	-0.23	0.52	0.4	0.38	-0.23	0.5	0.46	0.46	-0.3	0.17	-0.31	0.29	-0.09	0.47		0.45	0.4	0.37	0.46	0.45	0.25	0.26	-0.1	-0.29
Cash And Short Term Investments	1.0	0.95	-0.39	0.88	0.8	0.76	-0.4	0.75	0.72	0.37	-0.26	-0.2	-0.57	0.68	0.42	0.22	0.45		0.93	0.78	0.37	1.0	0.7	0.74	-0.5	-0.23
Short Term Investments	0.93	0.92	-0.32	0.76	0.7	0.61	-0.33	0.57	0.54	0.4	-0.21	-0.05	-0.45	0.53	0.23	0.26	0.4	0.93		0.68	0.4	0.93	0.61	0.64	-0.44	-0.19
Other Current Assets	0.78	0.6	-0.16	0.76	0.89	0.87	-0.16	0.93	0.92	0.44	-0.24	0.07	-0.83	0.87	0.16	0.28	0.37	0.78	0.68		0.44	0.78	0.73	0.75	-0.31	-0.21
Property Plant And Equipment Gross	0.32	0.18	-0.24	0.2	0.38	0.49	-0.24	0.46	0.46	1.0	0.52	0.48	-0.41	0.43	-0.34	0.93	0.46	0.37	0.4	0.44		0.37	0.5	0.51	-0.13	0.51
Total Current Assets	1.0	0.94	-0.39	0.88	0.8	0.76	-0.39	0.75	0.72	0.37	-0.26	-0.19	-0.57	0.69	0.42	0.22	0.45	1.0	0.93	0.78	0.37		0.71	0.74	-0.5	-0.23
Short Long Term Debt Total	0.7	0.47	-0.04	0.49	0.89	0.95	-0.05	0.81	0.84	0.5	-0.15	0.25	-0.87	0.84	0.05	0.47	0.25	0.7	0.61	0.73	0.5	0.71		1.0	-0.1	-0.15
Non Current Liabilities Total	0.74	0.5	-0.11	0.54	0.89	0.96	-0.12	0.83	0.85	0.51	-0.13	0.22	-0.85	0.85	0.08	0.45	0.26	0.74	0.64	0.75	0.51	0.74	1.0		-0.18	-0.14
Short Term Debt	-0.47	-0.52	0.82	-0.65	-0.1	-0.2	0.82	-0.31	-0.22	-0.13	-0.14	0.29	-0.09	-0.21	-0.32	0.15	-0.1	-0.5	-0.44	-0.31	-0.13	-0.5	-0.1	-0.18		-0.17
Net Receivables	-0.32	-0.31	-0.23	-0.34	-0.39	-0.22	-0.23	-0.24	-0.26	0.51	0.99	0.11	0.32	-0.22	-0.16	0.44	-0.29	-0.23	-0.19	-0.21	0.51	-0.23	-0.15	-0.14	-0.17

Click cells to compare fundamentals

Madrigal Pharmaceuticals Account Relationship Matchups

Madrigal Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	442.1M	287.0M	273.3M	362.6M	640.5M	672.6M
Total Stockholder Equity	416.6M	240.0M	196.1M	197.4M	405.3M	425.6M
Common Stock Shares Outstanding	15.4M	15.4M	16.5M	17.1M	18.7M	19.6M
Liabilities And Stockholders Equity	442.1M	287.0M	273.3M	362.6M	640.5M	672.6M
Other Stockholder Equity	639.6M	665.4M	863.5M	1.2B	1.7B	1.8B
Total Liab	25.5M	47.0M	77.2M	165.2M	235.2M	247.0M
Other Current Liab	23.6M	44.9M	54.6M	91.5M	89.5M	93.9M
Total Current Liabilities	25.1M	46.6M	76.8M	115.9M	118.5M	124.5M
Property Plant And Equipment Net	1.9M	1.8M	1.6M	1.2M	3.3M	2.1M
Net Debt	(46.0M)	(53.2M)	(35.5M)	(281.7M)	17.3M	18.1M
Retained Earnings	(223.2M)	(425.5M)	(667.3M)	(962.7M)	(1.3B)	(1.3B)
Accounts Payable	1.2M	1.0M	21.4M	23.8M	28.0M	29.4M
Cash	46.7M	54.0M	36.3M	331.5M	99.9M	99.8M
Non Current Assets Total	1.9M	1.8M	1.6M	1.2M	3.3M	2.4M
Non Currrent Assets Other	1.9M	1.8M	797K	1.2M	1.4M	719.9K
Cash And Short Term Investments	439.0M	284.1M	270.3M	358.8M	634.1M	665.8M
Short Term Investments	392.3M	230.1M	234.1M	27.2M	534.2M	560.9M
Other Current Assets	1.2M	2.0M	2.7M	2.6M	3.2M	3.3M
Property Plant And Equipment Gross	1.9M	1.8M	1.6M	1.2M	3.3M	2.1M
Total Current Assets	440.2M	285.2M	271.7M	361.4M	637.3M	669.1M
Accumulated Other Comprehensive Income	216K	47K	(80K)	(32K)	468K	491.4K
Non Current Liabilities Total	361K	468K	387K	49.3M	116.7M	122.5M
Net Tangible Assets	416.6M	240.0M	196.1M	197.4M	227.0M	184.4M
Retained Earnings Total Equity	(223.2M)	(425.5M)	(667.3M)	(962.7M)	(866.4M)	(823.1M)
Capital Surpluse	639.6M	665.4M	863.5M	1.2B	1.3B	1.4B
Property Plant Equipment	1.2M	1.0M	1.6M	601K	691.2K	734.4K
Net Invested Capital	416.6M	240.0M	196.1M	246.7M	520.8M	358.2M
Net Working Capital	415.1M	238.6M	194.8M	245.5M	518.7M	356.9M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports:

How To Invest In Madrigal

Details

Is Madrigal Stock a good investment?

Details

What is Madrigal Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.

You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(25.03)

Revenue Per Share

3.705

Return On Assets

(0.52)

Return On Equity

(1.30)

The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Madrigal Net Income vs Research Development Analysis

Net Income vs Research Development

Net Income vs Research Development Correlation Analysis

Correlation Coefficient

Net Income

Research Development

Madrigal Pharmaceuticals fundamental ratios Correlations

Madrigal Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Madrigal Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Common Stock	+ 1.0	Common Stock Total Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total

Cash	- 0.95	Net Debt
Retained Earnings	- 0.94	Other Stockholder Equity
Retained Earnings	- 0.92	Total Liab
Retained Earnings	- 0.9	Total Current Liabilities
Short Long Term Debt Total	- 0.87	Retained Earnings
Accounts Payable	- 0.87	Retained Earnings